-
Product Insights
Cajuina C5
Cajuina C5 is an Onshore Wind project located in Rio Grande do Norte, Brazil. The project is owned by AES Brasil Energia SA and is developed by JMalucelli Energia S.A; Serra Verde III Energetica SA. The project is at the permitting stage. Empower your strategies with our Cajuina C5 report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crovalimab in Paroxysmal Nocturnal Hemoglobinuria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crovalimab in Paroxysmal Nocturnal Hemoglobinuria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Crovalimab in Paroxysmal Nocturnal Hemoglobinuria Drug Details: Crovalimab (Piasky) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ravulizumab LA in Primary Progressive Multiple Sclerosis (PPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ravulizumab LA in Primary Progressive Multiple Sclerosis (PPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ravulizumab LA in Primary Progressive Multiple Sclerosis (PPMS)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ravulizumab LA in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ravulizumab LA in Lupus Nephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ravulizumab LA in Lupus Nephritis Drug Details: Ravulizumab (Ultomiris) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ravulizumab LA in Thrombotic Microangiopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ravulizumab LA in Thrombotic Microangiopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ravulizumab LA in Thrombotic Microangiopathy Drug Details: Ravulizumab (Ultomiris) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ravulizumab LA in Acute Renal Failure (ARF) (Acute Kidney Injury)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ravulizumab LA in Acute Renal Failure (ARF) (Acute Kidney Injury) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ravulizumab LA in Acute Renal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ravulizumab LA in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ravulizumab LA in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ravulizumab LA in Chronic Kidney Disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cemdisiran in Myasthenia Gravis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cemdisiran in Myasthenia Gravis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cemdisiran in Myasthenia Gravis Drug Details: Cemdisiran is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PMX-205 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PMX-205 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PMX-205 in Parkinson's Disease Drug Details: PMX-205 (TDI0116) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cemdisiran in Paroxysmal Nocturnal Hemoglobinuria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cemdisiran in Paroxysmal Nocturnal Hemoglobinuria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cemdisiran in Paroxysmal Nocturnal Hemoglobinuria Drug Details: Cemdisiran is under development...